HHS Rescinds Guidance on Gender-Affirming Care
HHS Rescinds Guidance on Gender-Affirming Care
- On February 20, 2025, the Department of Health and Human Services (HHS) Office for Civil Rights (OCR) rescinded prior guidance on gender-affirming care, entitled “HHS Notice and Guidance on Gender Affirming Care, Civil Rights, and Patient Privacy,” issued March 2, 2022 (2022 Guidance).
- Covered entities should no longer rely on the rescinded 2022 Guidance.
- OCR stated the rescission aligns the agency with the policy outlined in Executive Order 14187, that the agency will not promote, assist, or support the gender transition of a minor and will enforce all laws to prohibit or limit such procedures.
For questions, please reach out to Vicky Jucelin.
Related
On January 17, 2025, the Centers for Medicare & Medicaid Services (CMS) issued the list of 15 additional Part D drugs for the Medicare Drug Price Negotiation Program.
In January 2025, the U.S. Department of Health and Human Services (HHS) issued a Strategic Plan for the Use of Artificial Intelligence in Health, Human Services, and Public Health in efforts to use AI responsibly to improve people's lives.
On December 20, 2024, the Centers for Medicare & Medicaid Services (CMS) issued explanations for the maximum fair prices (MFPs) for the drugs selected for the IRA’s Medicare Drug Price Negotiation Program for the initial price applicability year (IPAY) 2026.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
